Advanced search    

Search: authors:"Satoshi Motoya"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Suzuki has received fees for lectures from AbbVie GK, Eisai Co. Ltd, Kyorin Pharmaceutical Co. Ltd, and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has received or is awaiting grant support from

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

Daiichi Hospital; Yutaka Endou, Showa University Fujigaoka Hospital. Conflict of interest Yasuo Suzuki received lecture fees from AbbVie, Mitsubishi Tanabe Pharma, and Zeria Pharmaceutical. Satoshi Motoya

An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn’s disease

Yoko Yokoyama 8 Katsuyoshi Matsuoka 7 Hiroki Takahashi 14 Ryuichi Iwakiri 13 Takayuki Yamamoto 12 Tomoo Nakagawa 11 Takumi Fukuchi 16 Satoshi Motoya 15 Reiko Kunisaki 10 Shingo Kato 5 Fumihito Hirai 6

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

AbbVie. Conflict of interest Yasuo Suzuki has received fees for lectures from AbbVie GK, Eisai Co, Ltd, Kyorin Pharmaceutical Co, Ltd, and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has received